. . "In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients."@en . "Cisapride is rapidly absorbed after oral administration, with an absolute bioavailability of 35-40%."@en . . "# Pearce RE, Gotschall RR, Kearns GL, Leeder JS: Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec;29(12):1548-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11717173"@en . . "cis-4-amino-5-chloro-N-{1-[3-(P-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl}-O-anisamide"@en . . . "Cisaprida"@en . "Alfons Gaston Maria De Knaep, Luc Jozef Raphael Moens, Max Rey, \"Synthesis of cisapride.\" U.S. Patent US6218542, issued January, 1988."@en . . . . "6-12 hours"@en . . "Grapefruit and grapefruit juice should be avoided throughout treatment, grapefruit can significantly increase serum levels of this product."@en . "Cisapride acts through the stimulation of the serotonin 5-HT₄ receptors which increases acetylcholine release in the enteric nervous system (specifically the myenteric plexus). This results in increased tone and amplitude of gastric (especially antral) contractions, relaxation of the pyloric sphincter and the duodenal bulb, and increased peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit."@en . "withdrawn"@en . "4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-3-methoxy-piperidin-4-yl}-2-methoxy-benzamide"@en . . . . "Cisapride"@en . . "4-amino-5-chloro-N-(1-(3-(4-Fluorophenoxy)propyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide"@en . . . . "Cisaprid"@en . . "97.5%"@en . . . . . "Cisapride"@en . . "Humans and other mammals"@en . . . . . . . . . . . . . " "@en . . . . . "(+-)-Cisapride"@en . " "@en . . . "approved"@en . . "cis-4-amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl}-2-methoxybenzamide"@en . . . . "cis-4-amino-5-chloro-N-(1-(3-(P-Fluorophenoxy)propyl)-3-methoxy-4-piperidyl)-O-anisamide"@en . "Cisapridum"@en . . . . . . . . "81098-60-4"@en . "For the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease."@en . "investigational"@en . . "Increases absorption, take 30 minutes before a meal."@en .